Strategic multi-platform collaboration to develop innovative oncology therapeutics
Drug Discovery World
SEPTEMBER 14, 2023
The strategic R&D collaboration focuses on three pillars: Applying Moderna’s mRNA technology for in vivo expression of Immatics’ next-generation, half-life extended TCR bispecifics (TCER), targeting cancer-specific HLA-presented peptides.
Let's personalize your content